Previous close | 1.6900 |
Open | 1.6600 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 1.6600 - 1.8022 |
52-week range | 1.6600 - 5.5000 |
Volume | |
Avg. volume | 18,094 |
Market cap | 17.059M |
Beta (5Y monthly) | 1.23 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | 05 Jun 2015 |
1y target est | N/A |
DUBLIN, Ireland, April 04, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors, today announced results for the quarter ended December 31, 2023 and fiscal year 2023 and key business updates. Business Updates Comprehensive Transformation Plan At the Emerging Growth Investor Conference on March 7, 2024, our new management team announced a comprehensive tra
Conference Call Scheduled for Thursday, April 4, 2024 at 8:00 AM ETDUBLIN, Ireland, March 28, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”), a leading developer and manufacturer of diagnostic solutions for the point-of-care and clinical laboratory markets, will report financial results for the fourth quarter and fiscal year 2023 on Thursday, April 4, 2024 at 8:00 AM ET. Conference Call Dial-In & Webcast Information Date:Thursday, April 4, 2024Time:8:00 AM ETUnited S
DUBLIN, Ireland, March 08, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech Plc. (NASDAQ: TRIB) (the “Company”) today reported the receipt of a formal notification from The Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with Listing Rule 5450(a)(1), which requires the Company's American Depositary Shares (“ADSs”) to maintain a minimum bid price of $1.00 per ADS. The Nasdaq staff made this determination of compliance after the closing bid price of the Company's was at $1.00 p